In light of the fixed-income status of many Medicare beneficiaries, concerns related to OOP costs often come into play
These cost concerns have the potential to adversely affect therapeutic adherence and, ultimately, overall patient health
Considering the high costs related to clotting factor concentrate, which comprise the majority of overall costs for patients, these OOP concerns frequently present near the beginning of the coverage year, prior to deductibles being met
Medigap enrollment may serve in alleviating some of these financial pressures, allowing beneficiaries to pay a premium for supplemental insurance and more evenly distribute OOP costs over the calendar year